Sep 16 |
Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths
|
Sep 16 |
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
|
Sep 16 |
Cancer Biotech Nuvalent’s Stock Jumps on Positive Data
|
Sep 16 |
Nuvalent jumps 19% on $350M equity offering
|
Sep 16 |
Nuvalent Announces Public Offering of Common Stock
|
Sep 14 |
Nuvalent, Inc. (NUVL): Among Hedge Funds’ Top Biotech Stock Picks
|
Sep 14 |
Nuvalent, Inc. (NUVL): Short Seller Sentiment is Bearish on This Cancer Stock
|
Sep 14 |
Nuvalent Highlights Presentation of Clinical Data at ESMO 2024 for Parallel Lead Programs for ROS1 and ALK-positive NSCLC and Accelerated Development Timelines
|
Sep 13 |
Nuvalent Announces Publication in Cancer Discovery Detailing Design and Characterization of ALK-selective inhibitor NVL-655
|
Sep 9 |
Updated Data for Nuvalent's ALK-Selective Inhibitor, NVL-655, and ROS1-Selective Inhibitor, Zidesamtinib, Continue to Support Potential Best-in-Class Profiles
|